Seattle Genetics Inc. asked AbbVie Inc. to continue manufacturing a component for its Adcetris drug.

The companies extended a development and supply agreement under which AbbVie will manufacture the anti-CD30 monoclonal antibody through Dec. 31, 2025, as opposed to Aug. 22, 2021, previously. The contract will automatically renew unless terminated by either party.

Adcetris is used for the treatment of classical Hodgkin lymphoma, a form of cancer that affects the immune system.